All Stories

  1. miR-505-3p controls chemokine receptor up-regulation in macrophages: role in familial hypercholesterolemia
  2. Acute Coronary Syndrome: The Risk to Young Women
  3. Delayed Care and Mortality Among Women and Men With Myocardial Infarction
  4. Tissue factor variants induce monocyte transformation and transdifferentiation into endothelial cell-like cells
  5. Adipose tissue depots and inflammation: effects on plasticity and resident mesenchymal stem cell function
  6. Position paper of the European Society of Cardiology–working group of coronary pathophysiology and microcirculation: obesity and heart disease
  7. Wnt signaling in the vessel wall
  8. Effects of Polyphenol Intake on Metabolic Syndrome: Current Evidences from Human Trials
  9. High density lipoproteins and kidney function: the friend turned foe?
  10. Macrophages of genetically characterized familial hypercholesterolaemia patients show up-regulation of LDL-receptor-related proteins
  11. Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis
  12. Bone Marrow Cell Transplant From Donors With Cardiovascular Risk Factors Increases the Pro-atherosclerotic Phenotype in the Recipients
  13. Risk factors' management to impact on acute coronary syndromes
  14. The International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC): 2010–2015
  15. Atheroma Burden and Morphology in Women
  16. Association of alcohol consumption with coronary artery disease severity
  17. Systems biology approaches to understand the effects of nutrition and promote health
  18. Inhibition of Notch rescues the angiogenic potential impaired by cardiovascular risk factors in epicardial adipose stem cells
  19. PCSK9: estructura y función. PCSK9 y receptor de lipoproteínas de baja densidad. Mutaciones y cambios derivados de estas
  20. Hypercoagulability and atrial fibrillation: a two-way road?
  21. DELAY TO HOSPITAL ADMISSION AND ACUTE CORONARY CARE IN THE ELDERLY AND IN THE VERY ELDERLY
  22. SEX-BASED DIFFERENCES IN SHORT TERM SURVIVAL AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION: THE ROLE OF SYSTEM DELAY
  23. Gene and Cell Therapy in Heart Failure
  24. Atherogenesis☆
  25. Tratamiento antiarrítmico actual de la fibrilación auricular no valvular en España. Datos del Registro FANTASIIA
  26. Biological actions of pentraxins
  27. A comprehensive study on different modelling approaches to predict platelet deposition rates in a perfusion chamber
  28. Growing thrombi release increased levels of CD235a+microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients
  29. The Role of Blood-Borne Microparticles in Inflammation and Hemostasis
  30. A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients
  31. Células madre mesenquimales derivadas de tejido adiposo y su potencial reparador en la enfermedad isquémica coronaria
  32. Adipose-derived Mesenchymal Stem Cells and Their Reparative Potential in Ischemic Heart Disease
  33. Circulating Endothelial Progenitor Cells and the Risk of Vascular Events after Ischemic Stroke
  34. LRP5 and plasma cholesterol levels modulate the canonical Wnt pathway in peripheral blood leukocytes
  35. Neutrophil extracellular traps: a new source of tissue factor in atherothrombosis
  36. rs11613352 Polymorphism (TT Genotype) Associates with a Decrease of Triglycerides and an Increase of HDL in Familial Hypercholesterolemia Patients
  37. El polimorfismo rs11613352 (genotipo TT) se asocia con disminución de triglicéridos y aumento de HDL en pacientes con hipercolesterolemia familiar
  38. El enriquecimiento de la dieta con polifenoles previene la disfunción endotelial coronaria mediante la activación de la vía de Akt/eNOS
  39. Polyphenol-enriched Diet Prevents Coronary Endothelial Dysfunction by Activating the Akt/eNOS Pathway
  40. LRP 5 deficiency down‐regulates Wnt signalling and promotes aortic lipid infiltration in hypercholesterolaemic mice
  41. Author reply
  42. Guidelines for Translational Research in Heart Failure
  43. Gene Expression, Atherogenesis, and the Mediterranean Diet
  44. Diagnóstico y tratamiento de la hipercolesterolemia familiar en España: documento de consenso
  45. Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor
  46. Notch Signaling Pathway Activation in Normal and Hyperglycemic Rats Differs in the Stem Cells of Visceral and Subcutaneous Adipose Tissue
  47. Beer elicits vasculoprotective effects through Akt/eNOS activation
  48. Lactobacillus plantarum CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response
  49. Experimental Cell Therapy
  50. Cardiomyocyte intracellular cholesteryl ester accumulation promotes tropoelastin physical alteration and degradation
  51. Thrombosis formation on atherosclerotic lesions and plaque rupture
  52. Changes in thrombus composition and profilin-1 release in acute myocardial infarction
  53. Glycoproteome of human apolipoprotein A-I: N- and O-glycosylated forms are increased in patients with acute myocardial infarction
  54. Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells
  55. Lipoprotein(a) Levels in Familial Hypercholesterolemia
  56. ROUTINE PERCUTANEOUS CORONARY INTERVENTION VERSUS MEDICAL THERAPY IN CLINICAL PRACTICE: THE ISACS-TC REGISTRY
  57. Qualitative and quantitative accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries
  58. Retinol-binding protein 4 levels and susceptibility to ischaemic events in men
  59. Diferencias en los mecanismos de acción de los nuevos antiagregantes: ¿cómo actúan?
  60. Amyloid-� Increases Metallo- and Cysteine Protease Activities in Human Macrophages
  61. Perspectives: The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide
  62. Perspectives: Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease
  63. Novel Methods for Accurate Identification, Isolation, and Genomic Analysis of Symptomatic Microenvironments in Atherosclerotic Arteries
  64. LRP 5 negatively regulates differentiation of monocytes through abrogation of Wnt signalling
  65. Systems biology approach to identify alterations in the stem cell reservoir of subcutaneous adipose tissue in a rat model of diabetes: effects on differentiation potential and function
  66. Endothelial progenitor cells in acute ischemic stroke
  67. Antiplatelet properties of natural products
  68. Presentation, management and outcomes of ischaemic heart disease in women
  69. Tissue Factor Induces Human Coronary Artery Smooth Muscle Cell Motility through Wnt-Signalling
  70. Low Density Lipoproteins Promote Unstable Calcium Handling Accompanied by Reduced SERCA2 and Connexin-40 Expression in Cardiomyocytes
  71. A Review of Macroscopic Thrombus Modeling Methods
  72. Introducción
  73. TLR-Dependent Pathways and Akt/mTOR/P70S6K Pathways in Cardiac Remodeling After Myocardial Infarction
  74. Models for the Study of Atherosclerosis and Thrombosis
  75. Mecanismos de acción de los diferentes agentes antiplaquetarios
  76. Adipose Tissue-Derived Mesenchymal Stem Cell and Angiogenesis in Ischemic Heart Disease
  77. Arterial Thrombosis: A Brief Overview
  78. C0074 Increased number of circulating and platelet-derived microparticles in human blood enhances thrombosis on atherosclerotic plaques
  79. Infiltrated cardiac lipids impair myofibroblast-induced healing of the myocardial scar post-myocardial infarction
  80. Intake of fermented beverages protect against acute myocardial injury: target organ cardiac effects and vasculoprotective effects
  81. Ets-1 transcription is required in tissue factor driven microvessel formation and stabilization
  82. Lipid Loading of Human Vascular Smooth Muscle Cells Induces Changes in Tropoelastin Protein Levels and Physical Structure
  83. LDL-Induced Impairment of Human Vascular Smooth Muscle Cells Repair Function Is Reversed by HMG-CoA Reductase Inhibition
  84. Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities
  85. Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk
  86. La hipoxia estimula la expresión del receptor LRP1 a través del factor de transcripción HIF-1α en células musculares lisas de pared vascular humana
  87. Incidence of diabetes and serum adipokines in Catalonian men. The ADIPOCAT study
  88. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos
  89. Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology
  90. Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type
  91. Erratum to: Evolution of Lipid Profiles after Bariatric Surgery
  92. Extracorporeal Assays of Thrombosis
  93. Evolution of Lipid Profiles after Bariatric Surgery
  94. EL CONSUMO DE FRUTAS Y HORTALIZAS AYUDA A PREVENIR EL DAÑO ENDOTELIAL
  95. Effects of rosuvastatin on the coordinated proteomic response of human coronary smooth muscle cells to low density lipoproteins
  96. Serum proteome in acute myocardial infarction
  97. Introducción: estatinas y salud cardiovascular
  98. Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?
  99. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion
  100. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction
  101. Specific Characteristics of Sudden Death in a Mediterranean Spanish Population
  102. Introducción: estatinas y salud cardiovascular
  103. Nanotechnology as a basis for the vascular treatment of atherosclerosis
  104. Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?
  105. Atherosclerosis and Thrombosis: Insights from Large Animal Models
  106. Simultaneous inhibition of TXA 2 and PGI 2 synthesis increases NO release in mesenteric resistance arteries from cirrhotic rats
  107. Nutraceuticals and Atherosclerosis: Human Trials
  108. New Challenges in the Etiopathogenesis of Atherothrombosis
  109. El neuron-derived orphan receptor-1 previene la apoptosis inducida por la hipoxia en las células endoteliales vasculares
  110. Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?
  111. Chapter 38 Atherosclerosis and thrombosis
  112. Modified C-Reactive Protein Is Expressed by Stroke Neovessels and Is a Potent Activator of Angiogenesis In Vitro
  113. La hipoxia induce la expresión de la lisil oxidasa (LOX) en células endoteliales
  114. Lipoproteínas, plaquetas y aterotrombosis
  115. Lipoproteins, Platelets, and Atherothrombosis
  116. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction
  117. Exogenous in vivo NO-donor treatment preserves p53 levels and protects vascular cells from apoptosis
  118. Nitric Oxide Donors as Platelet Inhibitors
  119. Thrombin in Arterial Thrombosis
  120. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin
  121. Controlling the angiogenic switch in developing atherosclerotic plaques: Possible targets for therapeutic intervention
  122. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano
  123. Increased PrPC expression correlates with endoglin (CD105) positive microvessels in advanced carotid lesions
  124. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin
  125. Expresión de la proteína C reactiva en placas ateroscleróticas de carótida
  126. Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario
  127. REPERFUSION INDUCES FAS (CD95) ACTIVATION IN CARDIOMYOCYTES IN A PIG MODEL OF ISCHEMIA-REPERFUSION
  128. Fundamentals of the thrombosis cascade
  129. The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetes mellitus patients but not in their relatives
  130. Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration
  131. Thrombin and protease-activated receptors (PARs) in atherothrombosis
  132. Coronary Atherothrombotic Disease: Progress in Antiplatelet Therapy
  133. Blood-Borne Tissue Factor Activity Predicts Major Cerebrovascular Events in Patients Undergoing Carotid Endarterectomy: Results from a 1-Year Follow-Up Study
  134. Platelets, Arterial Thrombosis and Cerebral Ischemia
  135. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis
  136. Aggregated low density lipoproteins decrease metalloproteinase-9 expression and activity in human coronary smooth muscle cells
  137. Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
  138. Influence of Statin Use on Endothelial Function: From Bench to Clinics
  139. Expresión de la lisil oxidasa (LOX) en la pared vascular: mecanismos implicados en la regulación de la LOX por lipoproteínas de baja densidad
  140. La LDL agregada induce la expresión y la activación de factor tisular en células vasculares mediante un mecanismo inhibible por pravastatina
  141. Protein disulphide isomerase-mediated LA419– NO release provides additional antithrombotic effects to the blockade of the ADP receptor
  142. D-dimer local expression is increased in symptomatic patients undergoing carotid endarterectomy
  143. Angina, “Normal” Coronary Angiography, and Vascular Dysfunction: Risk Assessment Strategies
  144. Elevation of E-Selectin Concentrations may Correlate with Potential Endothelial Dysfunction in Individuals with Hypopituitarism During Therapy with Growth Hormone
  145. Monounsaturated Fat and Cardiovascular Risk
  146. Monounsaturated Fat and Cardiovascular Risk
  147. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound
  148. Estatinas y ácidos grasos omega-3. Disminución de la mortalidad cardiovascular dependiente e independiente de la reducción de la colesterolemia
  149. Disfunción endotelial
  150. Líneas de investigación en el uso terapéutico del óxido nítrico
  151. Efecto temprano de las estatinas después de un infarto de miocardio. ¿Se debe a los efectos pleiotrópicos?
  152. Identification of Differential Protein Expression Associated with Development of Unstable Human Carotid Plaques
  153. NOR-1 is involved in VEGF-induced endothelial cell growth
  154. Disfunción endotelial
  155. Líneas de investigación en el uso terapéutico del óxido nítrico
  156. Estatinas y ácidos grasos omega-3. Disminución de la mortalidad cardiovascular dependiente e independiente de la reducción de la colesterolemia
  157. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering
  158. The pathophysiology of thrombosis
  159. High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells
  160. Antithrombotic effects of saratin on human atherosclerotic plaques
  161. Simvastatin potenciates PGI2 release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL
  162. A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters
  163. Atherogenesis
  164. Neovascularización en arterias coronarias humanas con distintos grados de lesión
  165. Pathogenesis of the acute coronary syndromes and therapeutic implications
  166. Differential intracellular trafficking of von Willebrand factor (vWF) and vWF propeptide in porcine endothelial cells lacking Weibel–Palade bodies and in human endothelial cells
  167. Neovascularización en arterias coronarias humanas con distintos grados de lesión
  168. Fisiopatología de la enfermedad aterotrombótica coronaria
  169. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels
  170. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin
  171. Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets
  172. Biología celular y molecular de las lesiones ateroscleróticas
  173. Antithrombotic effects of Abciximab
  174. Small oxidative changes in atherogenic LDL concentrations irreversibly regulate adhesiveness of human endothelial cells: effect of the lazaroid U74500A
  175. Reendotelización, engrosamiento intimal y remodelado vascular. ¿Un denominador común?
  176. Erratum to “Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition”
  177. Pathophysiology of Unstable Angina
  178. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors
  179. Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition
  180. Pathobiology of the arterial vessel wall
  181. Syndromes of Accelerated Atherosclerosis
  182. Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening
  183. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells
  184. Dissolution of Mural Thrombus by Specific Thrombin Inhibition With r-Hirudin : Comparison With Heparin and Aspirin
  185. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells
  186. Restenosis after Coronary Angioplasty
  187. A mimetic of the RGDF-peptide [arginine-glycine-aspartic acid-phenylalanine] blocks aggregation and flow-induced platelet deposition on severely injured stenotic arterial wall. Effects on different animal models and in humans
  188. 797-4 Comparative Effects of Heparin, Aspirin, and Hirudin on Thrombus Growth on Fresh Mural Thrombus: Deaggregation of Mural Thrombus by Specific Thrombin Inhibition
  189. 914-70 An Orally Active Synthetic IIb/IIIa Receptor Antagonist Inhibits Ex-vivo Platelet-Thrombus Formation
  190. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy
  191. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: Definition of a thrombotic shear rate threshold
  192. A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel wall in an in vivo porcine experimental model
  193. Thrombosis on atherosclerotic lesions: Implications for therapy
  194. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture
  195. Anticoagulant and Antiplatelet Therapy in Acute Coronary Syndromes and Atrial Fibrillation
  196. Echocardiographic “smoke” is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces
  197. Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation
  198. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
  199. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
  200. Changes in Vascular Geometry in Atherosclerotic Plaque Rupture and Its Relationship to Thrombosis in Acute Vascular Events
  201. Hirudin and other thrombin inhibitors experimental results and potential clinical applications
  202. The Porcine Model for the Understanding of Thrombogenesis and Atherogenesis
  203. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
  204. Importance of antithrombin therapy during coronary angioplasty
  205. Acute biologic response to excimer versus thermal laser angioplasty in experimental atherosclerosis
  206. Antithrombotic Therapy in Cardiovascular Diseases
  207. Vessel Wall-Related Risk Factors in Acute Vascular Events
  208. Coronary excimer laser angioplasty: Reduced complications and indium-111 platelet accumulation compared with thermal laser angioplasty
  209. 12 Antithrombotic therapy for coronary artery disease and valvular heart disease
  210. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation
  211. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
  212. Thrombosis and accelerated atherosclerosis in coronary bypass surgery and restenosis after percutaneous transluminal coronary angioplasty
  213. An acute surge of epinephrine stimulates platelet deposition to severely damaged vascular wall
  214. Platelet deposition on severely damaged vessel wall at flow conditions typical of stenotic vessel is inhibited by LJ-CP3. (antiplatelet glycoprotein GPIIB/IIIA monoclonal antibody)
  215. New approaches to treatment of myocardial infarction
  216. Interactions between blood and coronary arterial wall
  217. Platelet inhibitor agents in cardiovascular disease: An update
  218. Thrombosis on Stenosis: Mechanisms of Thrombus Growth and Embolization on Carotid Atherosclerotic Plaques
  219. Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction
  220. Insights into the pathogenesis of acute ischemic syndromes
  221. Prevention of Thromboembolism Induced by Prosthetic Heart Valves
  222. Thrombosis: Studies under Flow Conditions
  223. Summary.
  224. Cells and Aggregates at Surfaces
  225. Interactions of Platelets and Vessel Wall in the Development of Restenosis after Coronary Angioplasty
  226. Platelet/Vessel wall interactions, rheologic factors and thrombogenic substrate in acute coronary syndromes: Preventive strategies
  227. Restenosis after arterial angioplasty: A hemorrheologic response to injury
  228. Effect of High-Density Lipoproteins on Experimental Atherosclerosis
  229. Vascular Biology of Acute Coronary Syndromes
  230. Models of Behavior
  231. Pathophysiology of arterial thrombosis
  232. The clinical significance of markers of coagulation in acute coronary syndromes